Sean O’Farrell is a Senior Scientist within the R&D team at GammaDelta Therapeutics Limited., a young, London-based biotech startup company exploiting the unique properties of human tissue and blood-resident γδ T cells as a novel immunotherapy for cancer and inflammatory diseases. Before joining GammaDelta Therapeutics, Sean undertook cross-institutional PhD and postdoctoral training in the laboratory of Professor Adrian Hayday at King’s College London and The Francis Crick Institute. During his PhD and postdoc, Sean worked in collaboration with GlaxoSmithKline to further understand the immunological mechanisms of action of adjuvanted influenza vaccination and how these might drive vaccine efficacy and/or adverse events in a clinical setting. Within his current role, his primary interests include process understanding and utilising design of experiments to improve product function and phenotype within the cell therapy field. Sean’s primary responsibility in the organisation is to bridge cell therapy culture processes from R&D to process development.
